Publications by authors named "R Cavagna"
Article Synopsis
- LCINS accounts for 20% of lung cancer cases, with the study focusing on the molecular profile of driver genes in Brazilian patients who never smoked.
- The investigation involved studying mutational and gene fusion status in 119 lung adenocarcinomas using advanced sequencing techniques, alongside genetic ancestry analysis.
- Results showed high mutation rates in genes like EGFR and TP53, with significant findings on ancestry influencing mutation patterns, and highlighted that a large percentage of patients have potential targets for effective treatment.
Multiple myeloma (MM) cells from 1 out of 20 patient expressed high basal levels of membrane B-cell maturation antigen (BCMA, TNFRSF17, CD269), which was not upregulated by gamma-secretase inhibitor, suggesting a defective BCMA shedding by gamma-secretase. Genetic analyses of the patient's bone marrow DNA showed no mutations within the BCMA coding region, but rather partial deletion of PSEN1 and amplification of PSEN2, which encode alternative catalytic units of gamma-secretase. Altogether the data suggest that pt#12 MM cells express high and dysregulated BCMA with no shedding, due to genetic alterations of one or more gamma-secretase subunits.
View Article and Find Full Text PDFArticle Synopsis
- Immune checkpoint inhibitors (ICIs) have transformed treatment for non-small-cell lung cancer (NSCLC), but better methods for selecting patients who will benefit from these therapies are necessary, particularly through gene expression profiling (GEP).
- In a study involving 135 Brazilian NSCLC patients treated with ICIs, researchers analyzed GEP from tumor tissues and found that certain signatures, such as tumor inflammation signature (TIS) and IFN-γ, were linked to better outcomes.
- Patients with high TIS levels had significantly longer overall survival after immunotherapy (29.2 months) compared to those with low levels (15.5 months), indicating that TIS and IFN-γ could serve as valuable biomarkers to guide treatment choices
Introduction: TP53 is the most frequently mutated gene in lung tumors, but its prognostic role in admixed populations, such as Brazilians, remains unclear. In this study, we aimed to evaluate the frequency and clinicopathological impact of TP53 mutations in non-small cell lung cancer (NSCLC) patients in Brazil.
Methods: We analyzed 446 NSCLC patients from Barretos Cancer Hospital.